Veru Secures Novo Nordisk Supply Agreement for Phase 2b Obesity Trial, Grants Right of First Negotiation
VERU is trading near its 52-week low of $2.05 (9.8% above the low).
Summary
Veru Inc. entered a clinical supply agreement with Novo Nordisk for its Phase 2b obesity study, securing free Wegovy® supply and granting Novo Nordisk a right of first negotiation for future combinations.
Key Events · Product Development and Regulatory · VERU
-
Clinical Supply Agreement with Novo Nordisk
Veru Inc. entered into a clinical supply agreement with Novo Nordisk A/S for its Phase 2b PLATEAU clinical study, evaluating enobosarm in combination with Wegovy® for obesity.
-
Free Supply of Wegovy®
Novo Nordisk will supply Wegovy® (semaglutide for injection) to Veru at no charge for the duration of the Phase 2b PLATEAU study, significantly reducing Veru's trial expenses.
-
Right of First Negotiation Granted
Veru granted Novo Nordisk a right of first negotiation for future development, commercialization, or licensing of enobosarm intellectual property in combination with any Novo Nordisk GLP-1 product.
-
Veru Retains Commercialization Rights
Veru maintains full global development and commercialization rights to enobosarm, ensuring control over its primary asset.
Analysis · VERU · Life Sciences
This agreement with Novo Nordisk is a significant positive development for Veru, a small biotech company that recently reiterated a going concern warning. Securing free supply of Wegovy®, a leading GLP-1 RA, for its Phase 2b PLATEAU clinical study substantially reduces Veru's trial costs and provides external validation for its enobosarm combination therapy in obesity. The inclusion of a 'right of first negotiation' for Novo Nordisk on future combinations indicates a strategic interest from a major pharmaceutical player, potentially paving the way for a future partnership or licensing deal if the trial is successful. This strengthens Veru's financial position and clinical program credibility.
At the time of this filing, VERU was trading at $2.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.1M. The 52-week trading range was $2.05 to $7.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.